Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CSTL logo CSTL
Upturn stock ratingUpturn stock rating
CSTL logo

Castle Biosciences Inc (CSTL)

Upturn stock ratingUpturn stock rating
$20.42
Last Close (24-hour delay)
Profit since last BUY6.58%
upturn advisory
Consider higher Upturn Star rating
BUY since 5 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: CSTL (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

9 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $35.89

1 Year Target Price $35.89

Analysts Price Target For last 52 week
$35.89Target price
Low$15.45
Current$20.42
high$35.84

Analysis of Past Performance

Type Stock
Historic Profit -69.22%
Avg. Invested days 23
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 587.55M USD
Price to earnings Ratio -
1Y Target Price 35.89
Price to earnings Ratio -
1Y Target Price 35.89
Volume (30-day avg) 9
Beta 1.04
52 Weeks Range 15.45 - 35.84
Updated Date 06/30/2025
52 Weeks Range 15.45 - 35.84
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.19

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -1.46%
Operating Margin (TTM) -31.74%

Management Effectiveness

Return on Assets (TTM) -1.8%
Return on Equity (TTM) -1.2%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 337696036
Price to Sales(TTM) 1.69
Enterprise Value 337696036
Price to Sales(TTM) 1.69
Enterprise Value to Revenue 0.97
Enterprise Value to EBITDA 8.28
Shares Outstanding 28872300
Shares Floating 26464364
Shares Outstanding 28872300
Shares Floating 26464364
Percent Insiders 2.98
Percent Institutions 93.02

Analyst Ratings

Rating 3
Target Price 35.89
Buy 1
Strong Buy 8
Buy 1
Strong Buy 8
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Castle Biosciences Inc

stock logo

Company Overview

overview logo History and Background

Castle Biosciences Inc. was founded in 2005. It is a commercial-stage diagnostics company focused on providing personalized genomic information to improve cancer treatment decisions.

business area logo Core Business Areas

  • Dermatologic Cancers: Focuses on providing genomic tests for melanoma, cutaneous squamous cell carcinoma, and other skin cancers.
  • Other Cancers: Developing and commercializing tests for other cancers, including esophageal cancer.

leadership logo Leadership and Structure

Derek J. Maetzold is the President and CEO. The company has a board of directors overseeing its strategic direction.

Top Products and Market Share

overview logo Key Offerings

  • DecisionDx-Melanoma: A gene expression profile test to predict the risk of metastasis in cutaneous melanoma patients. Estimated 50% of the total addressable market (TAM). Competitors include Myriad Genetics (now part of Labcorp) and Interpace Biosciences.
  • DecisionDx-SCC: A gene expression profile test to predict the risk of metastasis in cutaneous squamous cell carcinoma patients. Competitors include virtually none (due to the unique gene panel used by Castle Biosciences Inc.)
  • TissueCypher Barrett's Esophagus Assay: A spatial systems biology test to predict the risk of progression to high-grade dysplasia and/or esophageal cancer in patients with Barrett's esophagus. Competitors include Exact Sciences.

Market Dynamics

industry overview logo Industry Overview

The market for personalized cancer diagnostics is growing, driven by increasing awareness of genomic testing and demand for tailored treatment strategies.

Positioning

Castle Biosciences is positioned as a leader in providing genomic information for dermatologic cancers, with a growing presence in other cancer areas. Its competitive advantage lies in its proprietary tests and clinical validation data.

Total Addressable Market (TAM)

The estimated total addressable market (TAM) for Castle Biosciences' current portfolio of tests is over $2 billion. They aim to capture significant share through expansion into new indications and penetration of existing markets.

Upturn SWOT Analysis

Strengths

  • Proprietary genomic tests
  • Strong clinical validation data
  • Experienced management team
  • Established sales and marketing infrastructure
  • Focus on unmet medical needs

Weaknesses

  • Reliance on single platform for revenue generation
  • Dependence on reimbursement from payers
  • Limited product portfolio outside dermatology
  • Relatively small company size compared to competitors

Opportunities

  • Expanding into new cancer indications
  • Increasing adoption of genomic testing
  • Developing new tests and technologies
  • Strategic partnerships and acquisitions
  • Expanding international presence

Threats

  • Competition from larger diagnostic companies
  • Changes in reimbursement policies
  • Technological advancements rendering tests obsolete
  • Regulatory hurdles
  • Economic downturn affecting healthcare spending

Competitors and Market Share

competitor logo Key Competitors

  • L
  • EXAS
  • ILMN
  • STVN

Competitive Landscape

Castle Biosciences' competitive advantage lies in its proprietary tests and clinical validation data. Larger competitors have broader product portfolios and greater financial resources.

Major Acquisitions

Myriad Genetics' dermatology business

  • Year: 2022
  • Acquisition Price (USD millions): 45
  • Strategic Rationale: Expanded Castle Biosciences' portfolio of dermatologic diagnostic tests and broadened its market reach.

AltheaDx

  • Year: 2021
  • Acquisition Price (USD millions): 158.5
  • Strategic Rationale: Enhance precision diagnostics in autoimmune and inflammatory diseases with complementary solutions.

BioDiagnostics, Inc. (BDI)

  • Year: 2023
  • Acquisition Price (USD millions): 20
  • Strategic Rationale: Enhance its offering to dermatologists for treatment management of patients with suspicious moles.

Growth Trajectory and Initiatives

Historical Growth: Castle Biosciences has experienced significant revenue growth in recent years, driven by increased adoption of its DecisionDx-Melanoma and DecisionDx-SCC tests.

Future Projections: Analysts expect continued revenue growth, driven by expansion into new indications and penetration of existing markets. Profitability is expected to improve in the coming years.

Recent Initiatives: Acquisition of companies with complementary technologies and tests, expansion of sales and marketing efforts, and development of new tests for other cancer types.

Summary

Castle Biosciences is a growing diagnostics company specializing in genomic tests for cancer, primarily focusing on dermatology. Revenue growth is strong, but profitability remains a challenge. Key strengths are proprietary tests and clinical validation, but the company faces competition and reimbursement risks. Expansion into new indications and strategic acquisitions offer opportunities for future growth, but reimbursement policies are a threat.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • SEC Filings (10-K, 10-Q), Company Website, Analyst Reports
  • Yahoo Finance
  • Company investor relations

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on your own research and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Castle Biosciences Inc

Exchange NASDAQ
Headquaters Friendswood, TX, United States
IPO Launch date 2019-07-25
Founder, CEO, President & Director Mr. Derek J. Maetzold
Sector Healthcare
Industry Diagnostics & Research
Full time employees 784
Full time employees 784

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a risk stratification spatial-omics test to predict future development of progression of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide optimal drug treatment for patients diagnosed with major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. The company offers its products to skin cancer and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.